Retour

Dr. med. Martin Heubner

Chefarzt Gynäkologie und Direktor des Departements Frauen und Kinder, Kantonsspital Baden

Martin Heubner ist seit 2016 Chefarzt für Gynäkologie und Direktor des Departements Frauen und Kinder am Kantonsspital Baden. Nach Beginn seiner klinischen Ausbildung am Klinikum Dortmund war er von 2005–2016 an der Universitätsfrauenklinik Essen tätig, zuletzt als Leitender Arzt für Gynäkologische Onkologie und operative Gynäkologie. Die Habilitation für das Fach Gynäkologie und Geburtshilfe erfolgte 2011, die Ernennung zum ausserplanmässigen Professor 2016. Seine Schwerpunkte liegen unter anderem in der gynäkologischen Onkologie und der operativen Gynäkologie, hier vor allem der minimalinvasiven Chirurgie sowie roboterassistierten Operationsverfahren. Er trägt den Schwerpunkttitel Gynäkologische Onkologie und absolvierte ein Studium zum Master of Health Business Administration, MHBA.

Littérature

Titre Auteur Journal Volume Pages Année
[01] Evaluation of a novel ELISA for the tumorassociated antigen CA 72-4 in patients with ovarian cancer. Buderath P, Kasimir-Bauer S, Aktas B, Rasch J, Kimmig R, Zeller T, Heubner M Future Sci. FSO145 2016
[2] Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA N Engl J Med 375(22) 2154-2164 2016
[3] Intraoperative Navigation in Robotically Assisted Compartmental Surgery of Uterine Cancer by Visualisation of Embryologically Derived Lymphatic Networks With Indocyanine-Green (ICG) Kimmig, R, Aktas B, Buderath P, Rusch P, Heubner M Journal of Surgical Oncology 2015/2016
[4] Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-Study Group (AGO-GYN8). Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner ML, Hanker L, Thiel F, Hilpert F. Gynecol Oncol 2015
[5] Embryologically based radical hysterectomy as peritoneal mesometrial resection (PMMR) with pelvic and para-aortic lymphadenectomy for loco-regional tumor control in endometrial cancer: first evidence for efficacy. Kimmig R, Iannaccone A, Aktas B, Buderath P, Heubner M Arch Gynecol Obstet 2015
[6] Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P The Lancet Oncology 2015
[7] Implementation of FAST-PET/MRI for whole-body staging of female patients with recurrent pelvic malignancies: A comparison to PET/CT. Grueneisen J, Schaarschmidt BM, Heubner M, Suntharalingam S, Milk I, Kinner S, Heubner A, Forsting M, Lauenstein T, Ruhlmann V, Umutlu L Eur J Radiol 2015
[8] Single nucleotide polymorphisms of the EpCAM-coding gene TACSTD1 in patients with ovarian cancer and their potential translational aspects. Heubner M, Wimberger P, Kasimir-Bauer S, Singer BB, Ruf P, Kimmig R, Siffert W. Arch Gynecol Obstet 2015
[9] Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results. Grueneisen J, Schaarschmidt BM, Heubner M, Aktas B, Kinner S, Forsting M, Lauenstein T, Ruhlmann V, Umutlu L Eur J Nucl Med Mol Imaging 2015
[10] Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up. Hoffmann O, Schroer-Zuendorf IA, Kasimir-Bauer S, Oberhoff C, Kimmig R, Heubner M Arch Gynecol Obstet 2015
[11] Diagnostic value of diffusion-weighted imaging in simultaneous 18F-FDG PET/MR imaging for whole-body staging of women with pelvic malignancies. Grueneisen J, Schaarschmidt BM, Beiderwellen K, Schulze-Hagen A, Heubner M, Kinner S, Forsting M, Lauenstein T, Ruhlmann V, Umutlu L. J Nucl Med 55(12) 1930-1935 2014
[12] Simultaneous Positron Emission Tomography/Magnetic Resonance Imaging for Whole-Body Staging in Patients With Recurrent Gynecological Malignancies of the Pelvis: A Comparison to Whole-Body Magnetic Resonance Imaging Alone. Grueneisen J, Beiderwellen K, Heusch P, Gratz M, Schulze-Hagen A, Heubner M, Kinner S, Forsting M, Lauenstein T, Ruhlmann V, Umutlu L Invest Radiol 2014
[13] Definition of compartment-based radical surgery in uterine cancer: radical hysterectomy in cervical cancer as 'total mesometrial resection (TMMR)' by M Höckel translated to robotic surgery (rTMMR). Kimmig R, Wimberger P, Buderath P, Aktas B, Iannaccone A, Heubner M World J Surg Oncol 2013
[14] Definition of compartment-based radical surgery in uterine cancer: modified radical hysterectomy in intermediate/high-risk endometrial cancer using peritoneal mesometrial resection (PMMR) by M Hockel translated to robotic surgery. Kimmig R, Aktas B, Buderath P, Wimberger P, Iannaccone A, Heubner M World J Surg Oncol 11(1) 198 2013
[15] Definition of compartment based radical surgery in uterine cancer-part I: therapeutic pelvic and periaortic lymphadenectomy by Michael Höckel translated to robotic surgery. Kimmig R, Iannaccone A, Buderath P, Aktas B, Wimberger P, Heubner M ISRN Obstet Gynecol 2013
[16] Utility of mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer. Aktas B, Kasimir-Bauer S, Wimberger P, Kimmig R, Heubner M Anticancer Res 33(1) 329-336 2013
[17] Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX®, clinicopathological markers and tumor cell dissemination in the blood and bone marrow. Aktas B, Bankfalvi A, Heubner M, Kimmig R, Kasimir-Bauer S. Mol Clin Oncol 1(6) 1049-1054 2013
[18] The haplotype of three polymorphisms in the SATB1 promoter region impacts survival in breast cancer patients. Heubner M, Kimmig R, Aktas B, Siffert W, Frey UH Onc Letters 2007-2012, 2014
[19] Morbidity of Inguinofemoral Lymphadenectomy in Vulval Cancer. Soliman AA, Heubner M, Kimmig R, Wimberger P ScientificWorldJournal 2012: 341253 2012
[20] Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study. Hoffmann O, Aktas B, Goldnau C, Heubner M, Oberhoff C, Kimmig R, Kasimir-Bauer S Anticancer Res 31(10) 3623-3628 2011
[21] Loss of heterozygosity proximal to the M6P/IGF2R locus is predictive for the presence of disseminated tumor cells in the bone marrow of ovarian cancer patients before and after chemotherapy. Kuhlmann JD, Schwarzenbach H, Otterbach F, Heubner M, Wimberger P, Worm KH, Kimmig R, Kasimir-Bauer S Genes Chromosomes Cancer 50(8) 598-605 2011
[22] Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy. Aktas B, Kasimir-Bauer S, Heubner M, Kimmig R, Wimberger P Int J Gynecol Cancer 21(5) 822-830 2011
[23] Circulating 20S proteasome in patients with non-metastasized breast cancer. Hoffmann O, Heubner M, Anlasik T, Winterhalter M, Dahlmann B, Kasimir-Bauer S, Kimmig R, Wohlschlaeger J, Sixt SU Anticancer Res 31(6) 2197-2201 2011
[24] The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer. Heubner M, Wimberger P, Dahlmann B, Kasimir-Bauer S, Kimmig R, Peters J, Wohlschlaeger J, Sixt SU Gynecol Oncol 120(2) 233-238 2011
[25] EpCAM-Autoantibody Levels in the course of disease of Ovarian Cancer patients. Heubner M, Errico D, Kasimir-Bauer S, Herlyn D, Kimmig R, Wimberger P Med Oncol 2010
[26] The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms. Heubner M, Wimberger P, Riemann K, Kasimir-Bauer S, Otterbach F, Kimmig R, Siffert W Oncol Res 18(7) 343-347 2010
[27] Increase in Circulating MicroRNA Levels in Blood of Ovarian cancer Patients. Roth C, Kasimir-Bauer S, Heubner M, Pantel K, Schwarzenbach H Circulating Nucleic Acids in Plasma and Serum 63-72 2010
[28] Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer. Wimberger P, Heubner M, Lindhofer H, Jäger M, Kimmig R, Kasimir-Bauer S Anticancer Res 29(5) 1787-1791 2009
[29] The AA genotype of a L1C G842A polymorphism is associated with an increased risk for ovarian cancer. Heubner M, Wimberger P, Kasimir-Bauer S, Otterbach F, Kimmig R, Siffert W Anticancer Res 29(8) 3449-3452 2009
[30] The haplotype of two FSHR polymorphisms in ovarian cancer - a potential role of ethnology in risk modification. Heubner M, Riemann K, Otterbach F, Kimmig R, Kasimir-Bauer S, Siffert W, Wimberger P Gynecol Oncol 112(3) 486-489 2009
[31] Prognostic relevance of the AQP5 -1364C>A polymorphism in primary breast cancer. Kasimir-Bauer S, Heubner M, Otterbach F, Kimmig R, Siffert W, Adamzik M. Mol Med Rep 2(4) 645-650 2009
[32] Association of the AA genotype of the BCL2 (-938C>A) promoter polymorphism with better survival in ovarian cancer. Heubner M, Wimberger P, Otterbach F, Kasimir-Bauer S, Siffert W, Kimmig R, Nückel H Int J Biol Markers 24(4) 223-229 2009
[33] Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer. Wimberger P, Heubner M, Otterbach F, Fehm T, Kimmig R, Kasimir-Bauer S Gynecol Oncol 107(2) 331-338 2007
Titre Auteur Journal Volume Pages Année
[01] Spätfolgen der Sectioentbindung: Narbendefekte und Plazentationsstörungen vorbeugen, erkennen, behandeln Köninger A, Winter A, Rusch P, Heubner M, Mach P, Kimmig R Der Gynäkologe 2017
[2] STIC (Serous Tubal Intraepithelial Carcinoma) – eine beunruhigende Zufallsdiagnose Heubner M FHA Frauenheilkunde Aktuell 1 36-39 2017
[3] Eine ungewöhnliche Adnexitis Heubner M, Krischer B FHA Frauenheilkunde Aktuell 2 27-31 2017
[4] ”Scars and stars” – MRI of Normal Findings and Complications After Cesarean Delivery. Kaniewska M, Hohl M; Schäffer L, Heubner M, Kubik-Huch RA MAGNETOM Flash 69 2-7 2017
[5] Gibt es einen Platz für roboterassistierte Chirurgie in der Gynäkologie? Heubner M FHA Frauenheilkunde Aktuell 3 & 4 52-55 2016
[6] ICG-gestützte Navigation bei der Chirurgie uteriner Malignome Kimmig R, Aktas B, Rusch P, Heubner M Der Gynäkologe 49 5 373-379 2016
[7] Robot-assisted hysterectomy: a critical evaluation Buderath P, Aktas B, Heubner M, Kimmig R Robotic Surgery: Research and Reviews 2 51–58 2015
[8] Robotic surgery in der Gynäkologie – Stand und Ausblick Kimmig R, Aktas B, Heubner M Gynäkologe 47 184–190 2014
[9] Peritoneale mesometriale Resektion (PMMR) als Kompartiment-basierte Operation. Technik beim „intermediate/high risk“ Endometriumkarzinom Kimmig R, Buderath P, Aktas B, Heubner M Gynäkologe 46 751–756 2013
[10] Endometriumkarzinom – operative Strategie und Adjuvanz. Ein möglicher Paradigmenwechsel. Kimmig R , Aktas B, Heubner M Gynäkologe 46 339–344 2013
[11] Hormonaktive Ovarialtumoren. Heubner M, Kimmig R Gynäkologe 45 352–354 2012
[12] Catumaxomab in the Treatment of Malignant Ascites: the Evidence of its Therapeutic Value. Wimberger P, Heubner M, Kimmig R Clinical Medicine Insights: therapeutics, Review 2 481-489 2010
[13] Primitiver neuroektodermaler Tumor des Ovars. Wimberger P, Heubner M, Wehling M, Nierwetberg D, Kasimir-Bauer S, Kimmig R Zentralbl Gynaekol 128 P1.10 14-15 2006
Retour